therapeutics

Novel Long-Acting Ghrelin Analogue PEP-064 Restores Energy Balance in C26 and Lewis Lung Carcinoma-Induced cachexia in Mice.

BACKGROUND

Cancer cachexia is a debilitating syndrome marked by involuntary weight loss resulting from reduced food intake and intricate metabolic reprogramming. Despite its high prevalence, cancer cachexia remains undertreated, with a lack of effective and approved pharmacotherapies. Ghrelin has emerged as...

🗓️ 2026-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreNovel Long-Acting Ghrelin Analogue PEP-064 Restores Energy Balance in C26 and Lewis Lung Carcinoma-Induced cachexia in Mice.

Longitudinal Assessment of Muscle Involvement in Late-Onset Pompe Disease Using Quantitative MRI: A Prospective Cohort Study.

BACKGROUND

Late-onset Pompe disease (LOPD) is a progressive metabolic myopathy characterised by lysosomal glycogen accumulation and leading to secondary disruptions in autophagy and cellular energy metabolism. While enzyme replacement therapy (ERT) has improved outcomes, early detection remains critical, because irreversible muscle...

🗓️ 2026-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLongitudinal Assessment of Muscle Involvement in Late-Onset Pompe Disease Using Quantitative MRI: A Prospective Cohort Study.

Restoration of circadian rhythm as novel targets against sarcopenia.

Sarcopenia, characterized by the age-related decline in skeletal muscle mass, strength, and function, is associated with high healthcare costs and significant health risks, including falls, fractures, functional decline, and mortality. Despite its prevalence and extensive research, there are currently no...

🗓️ 2026-05-31
📰 Publication: Chinese Medical Journal
Read MoreRestoration of circadian rhythm as novel targets against sarcopenia.

Sema4A Protects Against Muscle Atrophy and Promotes Repair by Regulating Intracellular Metabolic Signalling.

BACKGROUND

Skeletal muscle atrophy is a debilitating condition associated with diverse diseases and clinical interventions. Although triggers such as glucocorticoid excess or direct muscle injury disrupt the balance between protein homeostasis and tissue repair, the upstream molecular signals that actively preserve...

🗓️ 2026-05-30
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSema4A Protects Against Muscle Atrophy and Promotes Repair by Regulating Intracellular Metabolic Signalling.

Combined Bisoprolol and Megestrol Acetate Improves Survival and Preserves Cardiac Performance in a Rat Model of Cancer Cachexia.

BACKGROUND

Cancer cachexia is associated with rapid body wasting and cardiac dysfunction. Bisoprolol (BIS) and megestrol acetate (MA) improve selected cachexia phenotypes in the Yoshida AH-130 model, but their combined effects are not defined. We tested reduced-dose combined treatment of BIS...

🗓️ 2026-05-23
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCombined Bisoprolol and Megestrol Acetate Improves Survival and Preserves Cardiac Performance in a Rat Model of Cancer Cachexia.

Ginsenoside Ro ameliorates d-galactose-induced sarcopenia by modulating oxidative stress, inflammation, and gut microbiota in mice.

BACKGROUND

Sarcopenia is an age-related disorder primarily characterized by progressive muscle degeneration, and effective therapeutic interventions for this condition remain limited. Ginsenoside Ro (GRo) exhibits antioxidant and anti-inflammatory effects. However, the impact of GRo on skeletal muscle aging, myoblast differentiation, and...

🗓️ 2026-05-22
📰 Publication: Phytomedicine
Read MoreGinsenoside Ro ameliorates d-galactose-induced sarcopenia by modulating oxidative stress, inflammation, and gut microbiota in mice.

Body Composition Changes in Patients on GLP-1 Receptor Agonists Undergoing an Intensive Cardiac Rehabilitation Program.

BACKGROUND

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes and obesity and produce significant weight loss. However, concerns have emerged about potential loss of skeletal muscle mass (SMM) with pharmacologic weight reduction, particularly in older adults...

🗓️ 2026-05-21
📰 Publication: European Journal Of Preventive Cardiology
Read MoreBody Composition Changes in Patients on GLP-1 Receptor Agonists Undergoing an Intensive Cardiac Rehabilitation Program.

Heme Metabolism-Derived Carbon Monoxide Regulates Skeletal Muscle Function.

BACKGROUND

Heme oxygenases, HO-1 (Hmox1) and HO-2 (Hmox2), regulate skeletal muscle homeostasis by degrading heme and generating carbon monoxide (CO), a bioactive signalling molecule. Although HO-1 is known to influence muscle fibre composition and mitochondrial function, the role of HO-2 in...

🗓️ 2026-05-15
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreHeme Metabolism-Derived Carbon Monoxide Regulates Skeletal Muscle Function.

Why Osteosarcopenia Matters: Clinical and Investigative Implications.

BACKGROUND

Osteosarcopenia, the combination of osteoporosis and sarcopenia, is a geriatric syndrome linked to functional decline, falls, and fragility fractures. The interaction among bone, muscle, and their shared pathophysiology is driven by mechanical, metabolic, and hormonal factors. With global population aging...

🗓️ 2026-05-15
📰 Publication: European Journal Of Clinical Investigation
Read MoreWhy Osteosarcopenia Matters: Clinical and Investigative Implications.

Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

BACKGROUND

In a recent Phase 2 trial in patients with cancer cachexia, the anti-GDF-15 antibody ponsegromab resulted in increased body weight, appetite, muscle mass and physical activity. This study provides compelling evidence that targeting the GDF-15 pathway may offer a viable...

🗓️ 2026-05-13
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

Differential Branched-Chain Amino Acid Metabolism in Tissues of Tumor-Bearing Male Mice.

Cancer cachexia is a multifactorial syndrome characterized by involuntary loss of skeletal muscle and adipose tissue that is often resistant to nutritional support. The branched-chain amino acids (BCAA: leucine, isoleucine, and valine) stimulate protein synthesis, yet BCAA-targeted therapies have yielded...

🗓️ 2026-05-13
📰 Publication: American Journal Of Physiology-Regulatory Integrative And Comparative Physiology
Read MoreDifferential Branched-Chain Amino Acid Metabolism in Tissues of Tumor-Bearing Male Mice.

GDF10 exacerbates metastatic burden and cachexia in murine models of cancer.

Metastasis and cancer-induced cachexia significantly reduce survivorship and quality of life for cancer patients. GDF10 (BMP3b) is a TGF-ß superfamily ligand with little knowledge of its role in cancer progression. Some studies have shown that GDF10 exerts tumor-suppressive effects in...

🗓️ 2026-05-11
Read MoreGDF10 exacerbates metastatic burden and cachexia in murine models of cancer.

De novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.

Growth differentiation factor-15 (GDF15), a stress-responsive cytokine of the transforming growth factor-β superfamily, is elevated in cancer cachexia, chemotherapy-induced nausea, and hyperemesis gravidarum, making it both a biomarker and a therapeutic target. Here, we developed high-affinity GDF15 binders using an...

🗓️ 2026-05-09
📰 Publication: Experimental And Molecular Medicine
Read MoreDe novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.

Development of High-Affinity Ligands for Human UBR2.

UBR box-containing ubiquitin E3 ligases recognize the N-termini of their target proteins through the UBR box, and a member of the family, UBR2, has been established as a target to treat cancer- and diabetes-associated cachexia. However, the development of high-affinity...

🗓️ 2026-05-08
📰 Publication: Journal Of Medicinal Chemistry
Read MoreDevelopment of High-Affinity Ligands for Human UBR2.

Effectiveness and Safety of Interventions for Sarcopenia in Advanced Prostate Carcinoma: Systematic Review.

BACKGROUND

Sarcopenia has emerged as a potential prognostic factor in patients with advanced prostate cancer (PCa), requiring interventions for its prevention and treatment.

OBJECTIVE

We aimed to systematically identify, critically assess and synthesize the available evidence on the effectiveness and safety of interventions...

🗓️ 2026-05-06
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEffectiveness and Safety of Interventions for Sarcopenia in Advanced Prostate Carcinoma: Systematic Review.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!